Theralase Announces Acceptance of Peer Reviewed Publication for Next Generation Anti-Cancer Drugs

Toronto, Ontario – April 6, 2017

Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that its latest research has been accepted for peer reviewed publication, demonstrating that a new class of anti-cancer PDCs based on the metal Osmium (“Os”) may be very effective in the destruction of cancer.

A new publication entitled, “Novel Osmium-Based Coordination Complexes as Photosensitizers for Panchromatic Photodynamic Therapy” has recently been accepted for publication in Photochemistry and Photobiology, the official journal of the American Society of Photobiology.

Researchers from: Theralase; Acadia University, Department of Chemistry; the University of North Carolina at Greensboro, Department of Chemistry and Biochemistry; the University of Toronto, Department of Medical Biophysics and Princess Margaret Cancer Centre, University Health Network (“UHN”) collaborated on the publication.

Theralase’s lead PDC, TLD-1433, is based on the metal Ruthenium (“Ru”) and is currently under clinical investigation in a Phase Ib clinical study for Non-Muscle Invasive Bladder Cancer (“NMIBC”) at UHN.

This latest research demonstrates that Theralase’s next generation of Os based PDCs possess all and more of the significant characteristics of TLD-1433.

Cancer remains a major global issue requiring the advent of new, efficient and affordable treatments.

Photo Dynamic Therapy (“PDT”), which uses a light activated photosensitizer (“PS”) to produce Reactive Oxygen Species (“ROS”) in sufficient quantities to destroy cancer cells, has been established as an effective cancer treatment.

One of the current limitations of PDT technologies; however, has been the scarcity of PSs that can be activated over a wide range of wavelengths, to allow treatment at various tissue depths, and produce few, if any side effects. To address this shortcoming, three Os-based PSs were synthesized and their characteristics determined. Findings indicate that these PSs are able to be activated from Ultra Violet (“UV”) to Near InfraRed (“NIR”) light allowing for tissue penetrations from microns up to centimeters.

This new class of PDCs also have a strong resistance to photobleaching (ability to remain active in tissue until the cancer cells of interest have been destroyed) allowing for high energy, repeated laser irradiations of large tumour volumes, to systematically destroy cancerous tumours section by section, while minimizing effects to nearby healthy tissues.

Petri dish cell studies have demonstrated that these Os PSs have longer wavelength activation and efficacy in red and NIR light, in both normoxic (normal oxygen) and hypoxic (low oxygen) conditions, making them highly suitable for destruction of solid core cancer tumours, which generally present with hypoxic cores.

Previous Ru-based PSs, such as TLD-1433, have been able to be activated by red and NIR laser light, when combined with transferrin, but are more suitable when activated by blue and green laser light, relegating their use in clinical applications to superficial tumours, such as NMIBC.

The modular chemistry involved in synthesizing both the Ru and Os PSs is amenable to the preparation of large libraries of PDC platforms for targeting various cancer cells with high efficacy and low overall toxicity to healthy tissues.

Moreover, it has been demonstrated in this research that Os is a viable metal for building new therapeutic molecules despite the pervasive notion that Os is too toxic for clinical applications.

Dr. Arkady Mandel, MD, Phd, D.Sc., Chief Scientific Officer of Theralase stated that, “The latest published research supports the theory that Os PSs are well indicated to treat solid tumours, particularly when red or NIR light excitation is required to illuminate the entire tumour volume, such as brain cancers. Importantly, this is the first class of metal-based PSs that exhibit a direct panchromatic (activated by a wide spectrum of wavelengths) absorption from UV to NIR activation for PDT. For the first time, it may be possible to tune treatment depth to tumour invasion depth using a single PS, in which a single administration of the PS, followed by extended light administration (that could last several days) would enable the safest and most effective patient treatment outcomes.”

Roger Dumoulin-White, President and CEO of Theralase stated that, “Our scientific and biological teams, in collaboration with our chemistry and clinical research partners, utilize a methodical process to research and develop PDCs, such as this new class of Os PDCs. Theralase prides itself on combining the immense knowledge and understanding of all of its multi-disciplined teams and partners to research and develop PDCs, and the laser systems that activate them, in the quest to destroy a wide range of cancerous tumours.”

About Theralase Technologies Inc.

Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (TLTFF: OTC) in its Therapeutic Laser Technology (“TLT”) Division designs, manufactures, markets and distributes patented super-pulsed laser technology indicated for the treatment of chronic knee pain and in off-label use the elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy (“PDT”) Division researches and develops

specially designed molecules called Photo Dynamic Compounds (“PDCs”), which are able to localize to cancer cells and then when laser light activated, effectively destroy them.

Additional information is available at and .

This news release contains “forward-looking statements” which reflect the current expectations of management of the Corporation’s future growth, results of operations, performance and business prospects and opportunities. Such statements include, but are not limited to, statements regarding the proposed use of proceeds.. Wherever possible, words such as “may”, “would”, “could”, “should”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Corporation’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements; including, without limitation, those listed in the filings made by the Corporation with the Canadian securities regulatory authorities (which may be viewed at Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Corporation cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. The Corporation disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information:

Roger Dumoulin-White

President & CEO

1.866.THE.LASE (843-5273) ext. 225

416.699.LASE (5273) ext. 225